Discovery of potent and reversible MAO-B inhibitors as furanochalcones

被引:43
|
作者
Suresh, Jerad [1 ]
Baek, Seung Cheol [2 ]
Ramakrishnan, Surya Parakkot [1 ]
Kim, Hoon [2 ]
Mathew, Bijo [3 ,4 ]
机构
[1] Madras Med Coll & Govt Gen Hosp, Dept Pharmaceut Chem, Coll Pharm, Madras 600003, Tamil Nadu, India
[2] Sunchon Natl Univ, Inst Life Pharmaceut Sci, Dept Pharm & Res, Sunchon 57922, South Korea
[3] Ahalia Sch Pharm, Dept Pharmaceut Chem, Div Drug Design, Palakkad 678557, Kerala, India
[4] Ahalia Sch Pharm, Dept Pharmaceut Chem, Med Chem Res Lab, Palakkad 678557, Kerala, India
关键词
Furanochalcone; MAO-B; Reversible and competitive inhibitor; Potent; Molecular docking; MONOAMINE-OXIDASE-B; THIENYL CHALCONES; DERIVATIVES; BIOCHEMISTRY;
D O I
10.1016/j.ijbiomac.2017.11.159
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of twelve furanochalcones (F1-F12) was synthesized and investigated for their human monoamine oxidase inhibitory activities. Among the series, compound (2E, 4E)-1-(furan-2-yl)-5-phenylpenta-2, 4-dien-1-one (F1), which was analyzed by single-crystal X-ray diffraction, showed potent and selective MAO-B inhibitory activity with an inhibition constant (K-i) value of 0.0041 mu M and selectivity index of (SI) 172.4, and exhibited competitive inhibition. Introduction of a cinnamyl group to the furanochalcone significantly increased the inhibitory activity. In the dilution-recovery experiments, the residual activities of MAO-A and MAO-B by F1 under the diluted condition fully recovered as compared with the undiluted condition, indicating F1 is a reversible inhibitor. The K-i value of F1 is the lowest among the values of chalcone derivatives and furthermore lower than that (0.0079 mu M) of the reversible MAO-B inhibitor, lazabemide, a marketed drug. Molecular docking study against hMAO-B provided the binding site interactions of the lead compound, including strong pi-pi stacking between the phenyl system and FAD nucleus. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:660 / 664
页数:5
相关论文
共 50 条
  • [1] Identification of Indole-Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO-B Inhibitors
    Sasidharan, Rani
    Manju, Sreedharannair Leelabaiamma
    Ucar, Gulberk
    Baysal, Ipek
    Mathew, Bijo
    ARCHIV DER PHARMAZIE, 2016, 349 (08) : 627 - 637
  • [2] Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors
    Parambi, Della Grace Thomas
    Oh, Jong Min
    Baek, Seung Cheol
    Lee, Jae Pil
    Tondo, Anna Rita
    Nicolotti, Orazio
    Kim, Hoon
    Mathew, Bijo
    BIOORGANIC CHEMISTRY, 2019, 93
  • [3] Hydroxycoumarins as selective MAO-B inhibitors
    Serra, Silvia
    Ferino, Giulio
    Joao Matos, Maria
    Vazquez-Rodriguez, Saleta
    Delogu, Giovanna
    Vina, Dolores
    Cadoni, Enzo
    Santana, Lourdes
    Uriarte, Eugenio
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) : 258 - 261
  • [4] Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease
    Neudorfer, Catharina
    Shanab, Karem
    Jurik, Andreas
    Schreiber, Veronika
    Neudorfer, Carolina
    Vraka, Chrysoula
    Schirmer, Eva
    Holzer, Wolfgang
    Ecker, Gerhard
    Mitterhauser, Markus
    Wadsak, Wolfgang
    Spreitzer, Helmut
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (18) : 4490 - 4495
  • [5] New Frontiers in Selective Human MAO-B Inhibitors
    Carradori, Simone
    Silvestri, Romano
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (17) : 6717 - 6732
  • [6] Alkynyl-coumarinyl ethers as MAO-B inhibitors
    Mertens, Matthias D.
    Hinz, Sonja
    Mueller, Christa E.
    Guetschow, Michael
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (06) : 1916 - 1928
  • [7] Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs
    Helguera, A. M.
    Perez-Machado, G.
    Cordeiro, M. N. D. S.
    Borges, F.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (10) : 907 - 919
  • [8] Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders
    Koyiparambath, Vishal Payyalot
    Oh, Jong Min
    Khames, Ahmed
    Abdelgawad, Mohamed A.
    Nair, Aathira Sujathan
    Nath, Lekshmi R.
    Gambacorta, Nicola
    Ciriaco, Fulvio
    Nicolotti, Orazio
    Kim, Hoon
    Mathew, Bijo
    PHARMACEUTICS, 2021, 13 (06)
  • [9] Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease
    Nam, Min-Ho
    Park, Moosung
    Park, Hyeri
    Kim, Youngjae
    Yoon, Seulki
    Sawant, Vikram Shahaji
    Cho, Ji Won
    Park, Jong-Hyun
    Park, Ki Duk
    Min, Sun-Joon
    Lee, C. Justin
    Chooaii, Hyunah
    ACS CHEMICAL NEUROSCIENCE, 2017, 8 (07): : 1519 - 1529
  • [10] Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
    Finberg, John P. M.
    Rabey, Jose M.
    FRONTIERS IN PHARMACOLOGY, 2016, 7